JAMA Network highlights evidence that adding tumor debulking to first-line palliative chemotherapy did not improve survival and increased serious adverse events, reinforcing caution about aggressive surgery in widespread metastatic disease.
Tumor Debulking Might Not Improve Survival in Multiorgan Metastatic Disease
did not improve overall survival compared with chemotherapy alone
incidence of serious adverse events was higher
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare